Acera Surgical Publishes Manuscript Highlighting the Mechanism of Action of Nanofabricated Restrata™ Wound Matrix
St. Louis, MO— October 5th, 2017— Acera Surgical Inc., a bioscience company dedicated to the commercialization of fully synthetic electrospun scaffolds for medical applications, announced today the publication of scientific manuscript describing the mechanism of action of the Restrata™ Wound Matrix skin substitute in the Cureus Journal of Medical Science. Cureus Journal of Medical Science is a web-based peer-reviewed medical journal for a new generation of doctors and patients with global exposure. This is the second publication from Acera on Cureus this year. Cureus article
The publication, titled “What Makes the Optimal Wound Healing Material? A Review of Current Science and Introduction of a Synthetic Nanofabricated Wound Care Scaffold”, highlights the mechanism by which the unique nano-scale structure and architecture of Restrata™ Wound Matrix promotes and encourages tissue healing and wound closure when applied to the wound bed. The publication of the study ideally coincides with the successful use of the Restrata™ material in the treatment of over 90 wounds including: diabetic foot ulcers, venous leg ulcers, and burns.
“Acera is excited to highlight the unique mechanism by which Restrata™ ’s synthetic nanofiber matrix encourages new tissue formation, wound healing, and wound closure,” stated Dr. Matthew MacEwan, Chief Science Officer at Acera Surgical, Inc. “We are also extremely excited to see this mechanism in action on a day to day basis in the clinics as Restrata™ continues to heal numerous chronic wounds that are unresponsive to existing skin substitutes, including amniotic and allogenic materials.”
About Acera Surgical Inc.
Acera Surgical Inc., (“Acera,” St. Louis, Missouri) is a bioscience company developing and commercializing a portfolio of fully synthetic electrospun scaffolds for medical applications. Acera’s products exhibit a structure similar to native extracellular matrix (ECM) and thus support rapid and effective healing. The FDA cleared Acera’s first product, Cerafix® Dura Substitute, in 2016 and its second product, Restrata™ Wound Matrix, in 2017, both via 510(k), granting commercial access to markets exceeding $1.2B in revenue. Acera is currently raising Series A financing and seeking commercialization partners.
For additional information on Acera Surgical or the Restrata™ Wound Matrix, please visit http://www.acera-surgical.com.